The STD-HIV AIDS-2022 Conference brings together more than 1,200 public health professionals for the latest information on STD science, program, and policy. Join international leading researchers with government experts, clinical STD care providers, and state and local public health administrators for two days of cutting-edge plenary sessions, debates, and symposia that are sure to enlighten, challenge, and inspire how STD prevention and control is approached.
Why to Attend?
Experience 24-hour access to breaking science like never before. Not only will STD-HIV AIDS-2022: showcase the latest developments in HIV research, the conference will present brand-new data on COVID-19 and HIV, showcasing how HIV informs and intersects with the COVID-19 pandemic. From the latest advances in basic, clinical and prevention research to innovations in social sciences and new insights into effective programme roll out, access the science first and be a part of accelerating progress in the HIV response.
Whether you are a presenter, activist, scholarship recipient, young researcher or an exhibitor, pre-conference, satellite, or workshop organizer, STD-HIV AIDS-2022: Virtual gives you an innovative and interactive global platform to influence discussions on HIV science, research and policy. STD-HIV AIDS-2022: will bring delegates from around the world together, connecting to advance the HIV response.
STD-AIDS associations and societies
Dentists who provide care to individuals with HIV infection
Primary care providers
HIV or infectious disease specialists
Infectious Diseases Researchers
Viral Diseases Researchers
HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment.
AIDS is the late stage of HIV infection that occurs when the body’s immune system is badly damaged because of the virus.
A person with HIV is considered to have progressed to AIDS when: the number of their CD4 cells falls below 200 cells per cubic millimetre of blood (200 cells/mm3). (In someone with a healthy immune system, CD4 counts are between 500 and 1,600 cells/mm3.) OR they develop one or more opportunistic infections regardless of their CD4 count.
Without HIV medicine, people with AIDS typically survive about 3 years. Once someone has a dangerous opportunistic illness, life expectancy without treatment falls to about 1 year. HIV medicine can still help people at this stage of HIV infection, and it can even be lifesaving. But people who start ART soon after they get HIV experience more benefits that’s why HIV testing is so important.
STDs are sexually transmitted diseases. This means they are most often but not exclusively spread by sexual intercourse. HIV, chlamydia, genital herpes, genital warts, gonorrhea, some forms of hepatitis, syphilis, and trichomoniasis are STDs.
For Scientific Sessions please go through the link: https://globalhiv-aids-std.infectiousconferences.com/call-for-abstracts.php
For Abstract Submission please go through the link: https://globalhiv-aids-std.infectiousconferences.com/abstract-submission.php
Track-1: Transmission and Prevention
Transmission mainly through Various bodily fluids, such as vaginal secretions, semen, saliva, and blood, contain the bacteria or viruses involved. In some cases, a person can contract an STI by coming into direct contact with fluid that contains the bacteria or virus. To avoid contact with this fluid during oral, anal, or vaginal sex, use condoms or dental dams.
Using a condom correctly every time you have sex can help you avoid STDs. Condoms lessen the risk of infection for all STDs. You still can get certain STDs, like herpes or HPV, from contact with your partner's skin even when using a condom.
Track-2: Sexually Transmitted Diseases
Sexually transmitted infections (STIs) are very common among people who are sexually active. Anyone who has sex is at risk, including people with HIV, STIs are also commonly referred to as sexually transmitted diseases (STDs).
Track-3: Public Health
Public health professionals try to prevent problems from happening or recurring through implementing educational programs, recommending policies, administering services, and conducting research—in contrast to clinical professionals like doctors and nurses, who focus primarily on treating individuals after they become sick or injured. Public health also works to limit health disparities. A large part of public health is promoting health care equity, quality, and accessibility.
Track-4: Pediatric HIV
Human immunodeficiency virus (HIV) is the virus that is responsible for causing acquired immune deficiency syndrome (AIDS). The virus destroys or impairs cells of the immune system and progressively destroys the body's ability to fight infections and certain cancers. In adults and adolescents, HIV is most commonly spread by sexual contact with an infected partner. In most of the countries nearly all HIV infections in children under the age of 13 are from vertical transmission, which means the virus is passed to the child when they are in their mother's womb or as they pass through the birth canal, or through breastfeeding. Before 1985, a small group of children were infected with the virus by contaminated blood products. Routine screening of blood products began in 1985. Not every child born to an HIV-infected mother will acquire the virus conception
Track-5: 2. Diagnosis and Treatment
Infection with HIV causes an acute but brief and nonspecific influenza-like retroviral syndrome that can include fever, malaise, lymphadenopathy, pharyngitis, arthritis, or skin rash. Most persons experience at least one symptom; however, some might be asymptomatic or have no recognition of illness (406–409). Acute infection transitions to a multiyear, chronic illness that progressively depletes CD4+ T lymphocytes crucial for maintenance of effective immune function. Ultimately, persons with untreated HIV infection experience symptomatic, life-threatening immunodeficiency (i.e., AIDS).
Track-6: Clinical Research and Case Reports
STD’s clinical research help scientists find improved ways to prevent, detect, or treat HIV/AIDS and other sexually transmitted diseases. All the medications used to treat HIV/AIDS in the United States were first studied in clinical trials. HIV/AIDS clinical studies under way include studies of new medicines to inhibit or treat HIV, studies of vaccines to prevent or treat HIV, studies of medicines to treat infections correlated to HIV. Case report is the detailed information of the individual patient containing the symptoms, signs, diagnosis, and treatment and follows up of the patient. It is a demographic profile that usually describes an unusual or novel occurrence.
Track-7: Co-infections Associated with STD
It’s common for people with HIV to have other health issue, some of these issues may be directly related to HIV or its treatment. Others may be completely unrelated.
These health conditions can mean more doctors’ visits, lab tests, and medications to keep up with.
If you have HIV, the best thing you can do to stay healthy is to take HIV medicine (called antiretroviral therapy or ART) exactly as prescribed and get and keep an undetectable viral load a level of HIV in your blood so low that a standard lab test can’t detect it.
Track-8: Sexual Health
Sexual health is fundamental to the overall health and well-being of individuals, couples and families, and to the social and economic development of communities and countries. Sexual health, when viewed affirmatively, requires a positive and respectful approach to sexuality and sexual relationships, as well as the possibility of having pleasurable and safe sexual experiences, free of coercion, discrimination, and violence.
Track-9: HIV and Women's Health Issues
Women are disproportionately affected by HIV compared to men, with young women most at risk. In many countries, women experience inequality linked to cultural and social norms and many experience gender-based violence. These factors make women more likely to get HIV
Track-10: Recent Advancements
Recent developments to prevent the spread of HIV include pre-exposure prophylaxis (PrEP), which is the pre-emptive use of antiretroviral therapy by individuals substantially at risk of contracting the virus. However, researchers are still seeking to develop improved therapies and vaccines to combat the virus.
Track-11: Vaccines and People with HIV
Vaccines play an important role in keeping people healthy. They protect you against serious and sometimes deadly diseases.
Vaccines are especially important for people with chronic health conditions like HIV, which can make it harder to fight off vaccine-preventable diseases like pneumococcal disease or the flu. HIV can also make it more likely that you’ll have serious complications from those diseases, which is why getting recommended vaccines is an important part of your overall HIV medical care. HIV invasion of immune cells
Track-12: How Does COVID-19 Affect People with HIV?
We are still learning about COVID-19 including the Omicron variant—and how it affects people with HIV. This is an emerging, rapidly evolving situation and scientists are learning more every day.Global prevalence of HIV
Track-13: Testing and Health Monitoring
HIV/AIDS testing, monitoring and therapy have come a long way from the days when a diagnosis was a death sentence. Crucial parts of the effective treatment regimens developed in the last 40 years are consistent monitoring of the viral load (the amount of virus in the blood), and the immune cell count, which function as biological markers of the disease’s progression.CD4 count
Track-14: Alcohol and Drug Use
Alcohol and drug use can be harmful to your health and get out of hand for some people. Modest use of alcohol can help your heart health in some circumstances, but it can also lead to long-term effects that are harmful and reduce your ability to fight off HIV. Different drugs have different effects on the body, and they can affect your judgement, mental health, and physical health differently. The use of illegal drugs presents multiple risks to the health of people living with HIV including harmful effects on the body and the risks associated with injection drug use, and risks associated with sexual transmission of HIV.
Relevant Conferences: STD Conferences 2022 | STD Meetings 2022 | STD-HIV 2022 Amsterdam Meetings | STD-HIV AIDS-2022 Conferences | Epidemiology 2022 Conferences | Global HIV/AIDS Conferences | HIV 2022 Conferences Amsterdam | World wide STD Meetings 2022 | HIV/AIDS 2022 | Public Health Conferences Amsterdam | Epidemology 2022 Amsterdam Conferences | HIV Infection Conferences Netherlands | AIDS July Conferences | Virology 2022 Conferences | Pathogenesis July Conferences | Infectious Diseases Conferences | HIV Drug Resistance Conferences | AIDS Conferences 2022 | STI 2022 Conferences | STD 2022 Europe conferences
10th International Congress on Infectious Diseases January 23-24, 2023 Barcelona, Spain; 12th International Conference on Tropical Medicine and Infectious Diseases January 23-24 Barcelona, Spain; 18th World Congress on Infection Prevention and Control July 04-05, 2022 London, UK; 7th International Conference on Bacteriology July 11-12, 2022 Vienna, Austria; 13th International Conference on Emerging Infectious Diseases October 17-18, 2022 Barcelona, Spain; 24th International AIDS Conference July 29-August 02, 2022 Montreal, Canada; 2022 HIV Law & Practice Conference May 10-11 USA; Indiana University National HIV Conference June 8-11, 2022, in Indianapolis, Indiana; 16th International Conference on HIV, AIDS and Sexually Transmitted Infections December 02-03, 2022 in Amsterdam, Netherlands; British HIV Association Spring Conference 2022 April 20-22, 2022 Manchester, UK.
Europe: European AIDS Clinical Society / EACS BELGIUM, AIDS Action Europe Berlin, Germany, International AIDS Society, Switzerland, National Association of People Living With HIV/AIDS, European AIDS Clinical, UNAIDS, BHIVA, Deutsche AIDS Gesellschaft, German, International Union against Sexually Transmitted Infections (IUSTI), European Society for Immunodeficiencies, Association of Nurses in AIDS Care
USA: HIV.gov, USA, National AIDS Commission, HIV Medicine Association, American Sexually Transmitted Diseases Association (ASTDA), International Society for Infectious Diseases, Centers for AIDS Research (CFAR), Canadian Public Health Association, American Sexually Transmitted Diseases Association (ASTDA)
Asia Pacific: National AIDS Control Organization, HIV/AIDS Alliance, SAATHII, St. Maarten AIDS Foundation, Australian Federation of AIDS Organizations, AIDS SOCIETY OF INDIA, IASSTD & AIDS
The cost of HIV-related commodities has continued to decrease
Pricing for HIV-related treatment and prevention commodities continues to decrease, while pricing and procurement for diagnostic commodities is becoming more transparent and streamlined
Global funding discrepancies across countries tied to differences in progress against epidemic
Funding for HIV programs in LMICs has been relatively flat over the past few years, with only a 4 percent increase in international funding since 2010. However, total investment decreased by US $900 million between 2018 and 2021
Reduction of HIV-related deaths in recent years has been relatively stagnant
Although there has been a remarkable decline in HIV-related mortality over the last two decades from its peak of 1.7M estimated deaths in 2004, there are still over 750K AIDS related deaths each year, a number that has remained relatively stagnant despite ongoing improvements in ART coverage
HIV Drugs Market Study Report [2020-2027]
The HIV drugs market was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus, which attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. Over the years, the rise in prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help to prevent the multiplication of HIV virus, thereby reducing the risk of its transmission.
COVID-19 lockdowns and other restrictions disrupted HIV testing and in many countries led to steep drops in diagnoses and referrals to HIV treatment worldwide. The pandemic has impacted the growth of this market by suspending and resuming drug supplies. Additionally, declines in new prescriptions for patients in the US, Europe and other regions/countries affected by COVID have dampened global demand for antiretroviral and antibiotic products. In addition, failure of suppliers to deliver ARVs (antiretroviral drug) on time, shutdown of land & air transport services, and limited access to health services within countries as a result of the pandemic are anticipated to negatively impact the HIV drugs market in the future.
The major factors that boost the HIV drug market
The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an escalation in government initiatives to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments to control the HIV virus growth. Therefore, rise in awareness through such government initiatives is also expected to drive the HIV drugs market growth. However, stringent government regulations for the approval and commercialization of HIV drugs are expected to restrain the HIV drugs market growth.
Key Players of HIV Drugs Market
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
Gilead Sciences, Inc.
Johnson & Johnson,
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Market Sizing Analysis:
Each year, CHAI combines known regimen and formulation splits by country with pricing data to calculate the size of the ARV market in dollar terms, and to calculate the average cost of treatment for first- and second-line adult and pediatric patients. The assumed price paid for ARVs is informed by two sources: 1) South Africa procurement informs the weighted average price paid for each respective formulation within a given year for South Africa’s regimens and formulations; 2) For all other countries, the average Global Fund Pooled Procurement Mechanism (PPM) pricing across 2018 is used